Literature DB >> 15769935

Developmental expression and function of aldehyde reductase in proximal tubules of the kidney.

Oleg A Barski1, Victor Z Papusha, Margarita M Ivanova, Dorene M Rudman, Milton J Finegold.   

Abstract

Aldehyde reductase reduces a wide variety of toxic and physiological aldehydes with a marked preference for negatively charged substrates such as glucuronate. Reduction of glucuronate to gulonate is a step in inositol catabolism, a process specific to the kidney cortex. Administration of the aldehyde reductase inhibitor AL-1576 to mice increases urinary output of glucuronate and decreases output of vitamin C. Aldehyde reductase mRNA with a 319-bp 5'-untranslated region is expressed ubiquitously in murine tissues. A new isoform with a short 64-bp 5'-untranslated region is found predominantly in the kidney, resulting in 10-fold higher enzymatic activity observed in this organ compared with other tissues. A moderate level of the new transcript is found in liver, intestine, and stomach, whereas brain, heart, lung, spleen, ovary, and testis have low to insignificant levels. The short transcript is absent during embryonic development and is first observed in the murine kidney on postnatal day 6. The abundance of the short transcript and enzyme activity increase sigmoidally with age; the sharpest increase occurs during the third week of life. As shown by immunohistochemistry, aldehyde reductase expression is limited to the proximal tubules and parietal epithelium of Bowman's capsule. In the mouse, the intensity of staining in tubules increases with age, suggesting that induction of aldehyde reductase expression is part of renal tubular maturation. The human kidney also exhibits proximal tubular localization and the two mRNA transcripts of aldehyde reductase. Immunoreactive protein is present in the 9-wk-old fetal kidney, indicating that the induction of aldehyde reductase in humans occurs early in development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769935     DOI: 10.1152/ajprenal.00411.2004

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  10 in total

Review 1.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

2.  Transcriptional and post-translational modulation of myo-inositol oxygenase by high glucose and related pathobiological stresses.

Authors:  Baibaswata Nayak; Vinay K Kondeti; Ping Xie; Sun Lin; Navin Viswakarma; Kirtee Raparia; Yashpal S Kanwar
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

3.  Alternative splicing in the aldo-keto reductase superfamily: implications for protein nomenclature.

Authors:  Oleg A Barski; Rebekka Mindnich; Trevor M Penning
Journal:  Chem Biol Interact       Date:  2013-01-05       Impact factor: 5.192

4.  Novel associations between blood metabolites and kidney function among Bogalusa Heart Study and Multi-Ethnic Study of Atherosclerosis participants.

Authors:  Jovia L Nierenberg; Jiang He; Changwei Li; Xiaoying Gu; Mengyao Shi; Alexander C Razavi; Xuenan Mi; Shengxu Li; Lydia A Bazzano; Amanda H Anderson; Hua He; Wei Chen; Jason M Kinchen; Casey M Rebholz; Josef Coresh; Andrew S Levey; Lesley A Inker; Michael Shlipak; Tanika N Kelly
Journal:  Metabolomics       Date:  2019-11-13       Impact factor: 4.290

5.  Autoimmunity in membranous nephropathy targets aldose reductase and SOD2.

Authors:  Marco Prunotto; Maria Luisa Carnevali; Giovanni Candiano; Corrado Murtas; Maurizio Bruschi; Emilia Corradini; Antonella Trivelli; Alberto Magnasco; Andrea Petretto; Laura Santucci; Silvia Mattei; Rita Gatti; Francesco Scolari; Peter Kador; Landino Allegri; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2010-02-11       Impact factor: 10.121

6.  Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates.

Authors:  Susanne Weber; Joshua K Salabei; Gabriele Möller; Elisabeth Kremmer; Aruni Bhatnagar; Jerzy Adamski; Oleg A Barski
Journal:  J Biol Chem       Date:  2015-01-10       Impact factor: 5.157

7.  Ketohexokinase: expression and localization of the principal fructose-metabolizing enzyme.

Authors:  Christine P Diggle; Michael Shires; Derek Leitch; David Brooke; Ian M Carr; Alex F Markham; Bruce E Hayward; Aruna Asipu; David T Bonthron
Journal:  J Histochem Cytochem       Date:  2009-04-13       Impact factor: 2.479

8.  AKR1A1 Variant Associated With Schizophrenia Causes Exon Skipping, Leading to Loss of Enzymatic Activity.

Authors:  Kyoka Iino; Kazuya Toriumi; Riko Agarie; Mitsuhiro Miyashita; Kazuhiro Suzuki; Yasue Horiuchi; Kazuhiro Niizato; Kenichi Oshima; Atsushi Imai; Yukihiro Nagase; Itaru Kushima; Shinsuke Koike; Tempei Ikegame; Seiichiro Jinde; Eiichiro Nagata; Shinsuke Washizuka; Toshio Miyata; Shunya Takizawa; Ryota Hashimoto; Kiyoto Kasai; Norio Ozaki; Masanari Itokawa; Makoto Arai
Journal:  Front Genet       Date:  2021-12-06       Impact factor: 4.599

9.  Metabolite Biomarkers of CKD Progression in Children.

Authors:  Michelle R Denburg; Yunwen Xu; Alison G Abraham; Josef Coresh; Jingsha Chen; Morgan E Grams; Harold I Feldman; Paul L Kimmel; Casey M Rebholz; Eugene P Rhee; Ramachandran S Vasan; Bradley A Warady; Susan L Furth
Journal:  Clin J Am Soc Nephrol       Date:  2021-08       Impact factor: 10.614

10.  Reduced Acrolein Detoxification in akr1a1a Zebrafish Mutants Causes Impaired Insulin Receptor Signaling and Microvascular Alterations.

Authors:  Haozhe Qi; Felix Schmöhl; Xiaogang Li; Xin Qian; Christoph T Tabler; Katrin Bennewitz; Carsten Sticht; Jakob Morgenstern; Thomas Fleming; Nadine Volk; Ingrid Hausser; Elena Heidenreich; Rüdiger Hell; Peter Paul Nawroth; Jens Kroll
Journal:  Adv Sci (Weinh)       Date:  2021-07-18       Impact factor: 16.806

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.